Cargando…
Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk
Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups consisted of 1119 patients with liver cirrhosis of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509047/ https://www.ncbi.nlm.nih.gov/pubmed/34638908 http://dx.doi.org/10.3390/ijms221910560 |
_version_ | 1784582242780053504 |
---|---|
author | Rabekova, Zuzana Frankova, Sona Jirsa, Milan Neroldova, Magdalena Lunova, Mariia Fabian, Ondrej Kveton, Martin Varys, David Chmelova, Klara Adamkova, Vera Hubacek, Jaroslav A. Spicak, Julius Merta, Dusan Sperl, Jan |
author_facet | Rabekova, Zuzana Frankova, Sona Jirsa, Milan Neroldova, Magdalena Lunova, Mariia Fabian, Ondrej Kveton, Martin Varys, David Chmelova, Klara Adamkova, Vera Hubacek, Jaroslav A. Spicak, Julius Merta, Dusan Sperl, Jan |
author_sort | Rabekova, Zuzana |
collection | PubMed |
description | Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups consisted of 1119 patients with liver cirrhosis of various aetiologies, and 3240 healthy individuals served as population controls. The MZ genotype was significantly more frequent in the study group (55/1119 vs. 87/3240, p < 0.0001). The MS genotype frequency was comparable in controls (32/119 vs. 101/3240, p = 0.84). MZ and MS heterozygotes had lower serum AAT level than MM homozygotes (medians: 0.90 g/L; 1.40 g/L and 1.67 g/L; p < 0.001 for both). There were significantly fewer patients with HCC in the cirrhosis group among MZ and MS heterozygotes than in MM homozygotes (5/55 and 1/32 respectively, vs. 243/1022, p < 0.01 for both). The risk of HCC was lower in MZ and MS heterozygotes than in MM homozygotes (OR 0.3202; 95% CI 0.1361–0.7719 and OR 0.1522; 95% CI 0.02941–0.7882, respectively). Multivariate analysis of HCC risk factors identified MZ or MS genotype carriage as a protective factor, whereas age, male sex, BMI and viral aetiology of cirrhosis increased HCC risk. |
format | Online Article Text |
id | pubmed-8509047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85090472021-10-13 Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk Rabekova, Zuzana Frankova, Sona Jirsa, Milan Neroldova, Magdalena Lunova, Mariia Fabian, Ondrej Kveton, Martin Varys, David Chmelova, Klara Adamkova, Vera Hubacek, Jaroslav A. Spicak, Julius Merta, Dusan Sperl, Jan Int J Mol Sci Article Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups consisted of 1119 patients with liver cirrhosis of various aetiologies, and 3240 healthy individuals served as population controls. The MZ genotype was significantly more frequent in the study group (55/1119 vs. 87/3240, p < 0.0001). The MS genotype frequency was comparable in controls (32/119 vs. 101/3240, p = 0.84). MZ and MS heterozygotes had lower serum AAT level than MM homozygotes (medians: 0.90 g/L; 1.40 g/L and 1.67 g/L; p < 0.001 for both). There were significantly fewer patients with HCC in the cirrhosis group among MZ and MS heterozygotes than in MM homozygotes (5/55 and 1/32 respectively, vs. 243/1022, p < 0.01 for both). The risk of HCC was lower in MZ and MS heterozygotes than in MM homozygotes (OR 0.3202; 95% CI 0.1361–0.7719 and OR 0.1522; 95% CI 0.02941–0.7882, respectively). Multivariate analysis of HCC risk factors identified MZ or MS genotype carriage as a protective factor, whereas age, male sex, BMI and viral aetiology of cirrhosis increased HCC risk. MDPI 2021-09-29 /pmc/articles/PMC8509047/ /pubmed/34638908 http://dx.doi.org/10.3390/ijms221910560 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rabekova, Zuzana Frankova, Sona Jirsa, Milan Neroldova, Magdalena Lunova, Mariia Fabian, Ondrej Kveton, Martin Varys, David Chmelova, Klara Adamkova, Vera Hubacek, Jaroslav A. Spicak, Julius Merta, Dusan Sperl, Jan Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk |
title | Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk |
title_full | Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk |
title_fullStr | Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk |
title_full_unstemmed | Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk |
title_short | Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk |
title_sort | alpha-1 antitrypsin and hepatocellular carcinoma in liver cirrhosis: serpina1 mz or ms genotype carriage decreases the risk |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509047/ https://www.ncbi.nlm.nih.gov/pubmed/34638908 http://dx.doi.org/10.3390/ijms221910560 |
work_keys_str_mv | AT rabekovazuzana alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT frankovasona alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT jirsamilan alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT neroldovamagdalena alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT lunovamariia alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT fabianondrej alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT kvetonmartin alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT varysdavid alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT chmelovaklara alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT adamkovavera alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT hubacekjaroslava alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT spicakjulius alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT mertadusan alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk AT sperljan alpha1antitrypsinandhepatocellularcarcinomainlivercirrhosisserpina1mzormsgenotypecarriagedecreasestherisk |